US 12,453,719 B2
Treatment method using a complex of angiotensin II receptor antagonist metabolite and NEP inhibitor
Jingchao Sun, Guangdong (CN); Sirao Yang, Guangdong (CN); Lei Li, Guangdong (CN); Yue Yang, Guangdong (CN); Xuege Shen, Guangdong (CN); Wei Lin, Guangdong (CN); Shiying He, Guangdong (CN); and Ji Chen, Guangdong (CN)
Assigned to Shenzhen Salubris Pharmaceuticals Co., Ltd., Guangdong (CN)
Appl. No. 17/615,013
Filed by Shenzhen Salubris Pharmaceuticals Co., Ltd., Guangdong (CN)
PCT Filed May 26, 2020, PCT No. PCT/CN2020/092264
§ 371(c)(1), (2) Date Nov. 29, 2021,
PCT Pub. No. WO2020/238885, PCT Pub. Date Dec. 3, 2020.
Claims priority of application No. 201910462208.8 (CN), filed on May 30, 2019; and application No. 202010327793.3 (CN), filed on Apr. 23, 2020.
Prior Publication US 2022/0226285 A1, Jul. 21, 2022
Int. Cl. A61K 31/41 (2006.01); A61P 9/04 (2006.01)
CPC A61K 31/41 (2013.01) [A61P 9/04 (2018.01)] 13 Claims
 
1. A method for treating hypertension or heart failure, the method comprising administering 180-500 mg per day of a complex of an angiotensin II receptor antagonist metabolite and an NEP inhibitor to a patient, and the structural unit of the complex being as follows:
(aEXP3174·bAHU377)·xCa·nA
wherein a:b=1:0.25 to 4; x is a number between 0.5 and 3; A represents water; and n is a number between 0 and 3.